ClinicalTrials.Veeva

Menu

The Performance of da Vinci SP System on Extraperitoneal Approach Radical Prostatectomy (CGMH-SPEAR-P)

Chang Gung Medical Foundation logo

Chang Gung Medical Foundation

Status

Unknown

Conditions

Prostate Cancer

Treatments

Device: da Vinci SP system

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05403190
202101419A0C601

Details and patient eligibility

About

The objective of this study is to evaluate the performance and safety of da Vinci Single Port (SP) system on the surgery for extraperitoneal approach radical prostatectomy

Full description

Enrolled subjects would receive extraperitoneal approach radical prostatectomy using da Vinci SP system and be assessed at baseline (preoperatively), during hospitalization, and postoperatively (at 1 month +/-4 days, 3 month +/- 7 days, 6 months +/- 10 days, 12month +/-14 days). The preoperative assessment includes any diagnostic tests to confirm the subjects' cancer status and eligibility for the intervention under consideration such as transrectal or transperineal biopsy, image studies for staging including MRI/CT and bone scan, and cardiopulmonary tests to evaluate risks for anesthesia. The hospitalization assessment includes the collection of perioperative and postoperative details, conversions, and complications. The postoperative assessment includes regular follow up studies to evaluate cancer status and functional outcome (For sexual function, the International Index of Erectile Function (IIEF-5) would be recorded before and after the surgery. For continence, the number of pads per day and 24hr total weight of pads would be recorded. No pad used or one safe pad per day with net wet ≤ 50gm would be considered as continent. International Prostate Symptom Score (IPSS) wound be recorded before and after the surgery to access voiding function).

Enrollment

30 estimated patients

Sex

Male

Ages

18 to 78 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with biopsy-proved prostate cancer
  2. Stage clinical T1-T2N0M0
  3. Prostate volume ≦ 70cm (by transrectal ultrasound or other image studies)
  4. BMI ≦ 35 kg/m
  5. Low priority of nerve sparing (pre-op sexual dysfunction or don't care about sexual function)
  6. Age between 18 and 78 years old
  7. Suitable for minimally invasive surgery
  8. Patients willing and able to provide informed consent
  9. Patients willing and able to comply with study protocol requirements and follow-up

Exclusion criteria

  1. Previous abdominal or pelvic major operation history

  2. Previous radiation treatment to the pelvic area

  3. Patients received transurethral resection of prostate in three months

  4. Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions

    • Severe heart disease (NYHA functional class III-IV)
    • Severe lung disease (GOLD Group C-D)
  5. Anatomy unsuitable for endoscopic visualization or minimally invasive surgery

  6. Hemodynamic or respiratory instability after anesthesia

  7. Working space restriction (e.g. kyphosis or severe scoliosis)

  8. Emergency surgery

  9. Untreated active infection

  10. vulnerable populations

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

Study arm
Experimental group
Description:
Patients with prostate cancer
Treatment:
Device: da Vinci SP system

Trial contacts and locations

1

Loading...

Central trial contact

Hung-Jen Wang, MD; Po-Hung Lin, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems